RESUMO
Although the incidence of HIV among women on probation, parole and alternatives to incarceration programs is significant to public health, drivers of this concentrated epidemic among women under community corrections remain understudied. This study examined prevalence of HIV and sexually transmitted infections and the associations between substance use, socio-demographic factors and the prevalence of biologically-confirmed HIV and other sexually transmitted infections among a sample of 337 substance-using women recruited from community correction sites in New York City. Prevalence of HIV was 13% and sexually transmitted infections was 26% ( Chlamydia, trachomatis and Neisseria gonorrhea). After adjusting for covariates, HIV-positive women were 1.42 times more likely to use crack/cocaine than HIV-negative women (95% CI = 1.05-1.92). HIV-positive women were 25% less likely than HIV-negative women to report any unprotected vaginal and anal sex with their main partner (95% CI = 0.57-0.99). They were 70% less likely than HIV-negative women to report unprotected vaginal sex with a non-paying casual partner (95% CI = 0.1-0.9) and 22% less likely to report unprotected vaginal sex across all partners (95% CI = 0.61-0.99). Community corrections settings may be optimal venues to launch HIV/sexually transmitted infections prevention that have potential to reach and engage an ever-growing number of substance-using women.
Assuntos
Infecções por HIV/epidemiologia , Prisioneiros/estatística & dados numéricos , Infecções Sexualmente Transmissíveis/epidemiologia , Abuso de Substâncias por Via Intravenosa/epidemiologia , Sexo sem Proteção , Adulto , Chlamydia trachomatis , Feminino , Infecções por HIV/diagnóstico , Humanos , Neisseria gonorrhoeae , Cidade de Nova Iorque/epidemiologia , Prevalência , Fatores de Risco , Assunção de Riscos , Comportamento Sexual , Infecções Sexualmente Transmissíveis/diagnóstico , Fatores Socioeconômicos , Abuso de Substâncias por Via Intravenosa/complicações , Adulto JovemRESUMO
OBJECTIVES: To test the efficacy of a computerized, group-based HIV and intimate partner violence (IPV) intervention on reducing IPV victimization among substance-using women mandated to community corrections. METHODS: Between November 2009 and January 2012, we randomly allocated 306 women from community corrections in New York City to 3 study arms of a computerized HIV and IPV prevention trial: (1) 4 group sessions intervention with computerized self-paced IPV prevention modules (Computerized Women on the Road to Health [WORTH]), (2) traditional HIV and IPV prevention intervention group covering the same HIV and IPV content as Computerized WORTH without computers (Traditional WORTH), and (3) a Wellness Promotion control group. Primary outcomes were physical, injurious, and sexual IPV victimization in the previous 6 months at 12-month follow-up. RESULTS: Computerized WORTH participants reported significantly lower risk of physical IPV victimization, severe injurious IPV victimization, and severe sexual IPV victimization at 12-month follow-up when compared with control participants. No significant differences were seen between Traditional WORTH and control participants for any IPV outcomes. CONCLUSIONS: The efficacy of Computerized WORTH across multiple IPV outcomes highlights the promise of integrating computerized, self-paced IPV prevention modules in HIV prevention groups.
Assuntos
Infecções por HIV/prevenção & controle , Promoção da Saúde/organização & administração , Violência por Parceiro Íntimo/prevenção & controle , Prisões/organização & administração , Maus-Tratos Conjugais/prevenção & controle , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Adulto , Vítimas de Crime , Feminino , Infecções por HIV/epidemiologia , Humanos , Violência por Parceiro Íntimo/estatística & dados numéricos , Pessoa de Meia-Idade , Cidade de Nova Iorque/epidemiologia , Fatores de Risco , Comportamento Sexual/estatística & dados numéricos , Método Simples-Cego , Fatores Socioeconômicos , Maus-Tratos Conjugais/estatística & dados numéricosRESUMO
BACKGROUND: The high rate of intimate partner violence (IPV) victimisation found among substance-using women receiving community supervision underscores the need for effective IPV victimisation screening, brief intervention and referral to treatment services (SBIRT) for this population. AIMS: This randomised controlled trial (RCT) aims to assess the feasibility, safety and efficacy of a single-session computerised self-paced IPV SBIRT (Computerised WINGS) in identifying IPV victimisation among women under community supervision and increasing access to IPV services, compared to the same IPV SBIRT service delivered by a case manager (Case Manager WINGS). METHODS: This RCT was conducted with 191 substance-using women in probation and community court sites in New York City. RESULTS: No significant differences were found between Computerised and Case Manager WINGS arms on any outcomes. Both arms reported identical high rates of any physical, sexual or psychological IPV victimisation in the past year (77% for both arms) during the intervention. Both arms experienced significant increases from baseline to the 3-month follow-up in receipt of IPV services, social support, IPV self-efficacy and abstinence from drug use. CONCLUSIONS: Findings suggest that both modalities of WINGS show promise in identifying and addressing IPV victimisation among substance-using women receiving community supervision.
Assuntos
Vítimas de Crime/reabilitação , Violência por Parceiro Íntimo/psicologia , Programas de Rastreamento , Encaminhamento e Consulta/estatística & dados numéricos , Transtornos Relacionados ao Uso de Substâncias/terapia , Adulto , Bullying , Usuários de Drogas , Estudos de Viabilidade , Feminino , Objetivos , Humanos , Violência por Parceiro Íntimo/prevenção & controle , Pessoa de Meia-Idade , Características de Residência , Comportamento Sexual , Transtornos Relacionados ao Uso de Substâncias/psicologia , Resultado do Tratamento , Adulto JovemRESUMO
IMPORTANCE: This study is designed to address the need for evidence-based HIV/STI prevention approaches for drug-involved women under criminal justice community supervision. OBJECTIVE: We tested the efficacy of a group-based traditional and multimedia HIV/STI prevention intervention (Project WORTH: Women on the Road to Health) among drug-involved women under community supervision. DESIGN, SETTING, PARTICIPANTS, AND INTERVENTION: We randomized 306 women recruited from community supervision settings to receive either: (1) a four-session traditional group-based HIV/STI prevention intervention (traditional WORTH); (2) a four-session multimedia group-based HIV/STI prevention intervention that covered the same content as traditional WORTH but was delivered in a computerized format; or (3) a four-session group-based Wellness Promotion intervention that served as an attention control condition. The study examined whether the traditional or multimedia WORTH intervention was more efficacious in reducing risks when compared to Wellness Promotion; and whether multimedia WORTH was more efficacious in reducing risks when compared to traditional WORTH. MAIN OUTCOMES AND MEASURES: Primary outcomes were assessed over the 12-month post-intervention period and included the number of unprotected sex acts, the proportion of protected sex acts, and consistent condom use. At baseline, 77% of participants reported unprotected vaginal or anal sex (nâ=â237) and 63% (nâ=â194) had multiple sex partners. RESULTS: Women assigned to traditional or multimedia WORTH were significantly more likely than women assigned to the control condition to report an increase in the proportion of protected sex acts (ßâ=â0.10; 95% CIâ=â0.02-0.18) and a decrease in the number of unprotected sex acts (IRRâ=â0.72; 95% CIâ=â0.57-0.90). CONCLUSION AND RELEVANCE: The promising effects of traditional and multimedia WORTH on increasing condom use and high participation rates suggest that WORTH may be scaled up to redress the concentrated epidemics of HIV/STIs among drug-involved women in the criminal justice system. TRIAL REGISTRATION: ClinicalTrials.gov NCT01784809.